ArticlePolymers2025
Development and Characterization of Chitosan Microparticles via Ionic Gelation for Drug Delivery.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fabrication of Chitosan Hybrid Particles with Shrimp Shell Protein Hydrolysate-EGCG Conjugates for Antioxidant Protection in Lipid Systems.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study explores the formulation of chitosan microparticles through ionic gelation and presents detailed physicochemical characterization, release studies, and the utility and potential uses for drug delivery. Three formulations were prepared under rate-controlled conditions (stirring at 800 rpm and pH maintained at 4.6) with and without stabilizers to examine the effects of formulation parameters on particle morphology and structural stability. To determine different structural and chemical characteristics, Attenuated Total Reflectance Fourier-Transform Infrared spectroscopy (ATR-FTIR), Scanning Electron Microscopy (SEM), and dynamic light scattering (DLS) were utilized, which confirmed that the particles formed and assessed size distribution and structural integrity. Atomic force microscopy (AFM) was used to quantify surface roughness and potential nanomechanical differences that may derive from the use of different modifiers. Coformulation of bovine serum albumin (BSA) permitted assessment of encapsulation efficiency and drug release capacity. Based on in vitro release evidence, the protein released at a different rate, and the dispersion of formulations under physiological conditions (PBS, pH 7.4, 37 °C) confirmed the differences in stability between formulations. The tunable physical characteristics, mild fabrication conditions, and controlled drug release demonstrated that the chitosan particles could have useful relevance as a substrate for localized drug delivery and as a bioactive scaffold for tissue regenerative purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.